Savara (NASDAQ:SVRA) Share Price Breaks Above Fifty Day Moving Average – Should You Sell?

Savara Inc. (NASDAQ:SVRA – Get Free Report) shares passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $4.88 and traded as high as $5.34. Savara shares last traded at $5.21, with a volume of 12,260,866 shares changing hands.

Key Savara News

Here’s some of the latest news about SVRA:

  • Positive Sentiment: HC Wainwright maintained a Buy rating while lowering its price target from $10 to $9, still implying substantial potential upside from the quoted share price. HC Wainwright rating
  • Negative Sentiment: The FDA told Savara it would not act on the molgramostim BLA by the PDUFA date. The missed review deadline is the key near-term negative catalyst, postponing regulatory clarity for the drug candidate. Savara FDA update Reuters report

Analysts Set New Price Targets

Several research firms recently weighed in on SVRA. Citigroup reissued a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. HC Wainwright decreased their target price on shares of Savara from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. JPMorgan Chase & Co. began coverage on Savara in a research report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price objective for the company. Finally, Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average target price of $10.14.

Read Our Latest Research Report on Savara

Savara Trading Down 18.2%

The stock has a market capitalization of $939.84 million, a PE ratio of -6.98 and a beta of 0.32. The firm has a 50 day moving average price of $4.86 and a 200 day moving average price of $5.31. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.28.

Savara (NASDAQ:SVRA – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. Equities analysts expect that Savara Inc. will post -0.67 EPS for the current fiscal year.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP raised its position in shares of Savara by 6,524.4% in the 3rd quarter. Quarry LP now owns 11,924 shares of the company’s stock worth $62,000 after acquiring an additional 11,744 shares in the last quarter. Jump Financial LLC purchased a new position in Savara in the 3rd quarter worth $720,000. Marshall Wace LLP increased its holdings in Savara by 2.1% in the 3rd quarter. Marshall Wace LLP now owns 6,386,775 shares of the company’s stock worth $32,956,000 after buying an additional 129,786 shares during the period. Nantahala Capital Management LLC raised its holdings in shares of Savara by 2.3% during the third quarter. Nantahala Capital Management LLC now owns 7,137,159 shares of the company’s stock worth $36,828,000 after purchasing an additional 160,349 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. raised its stake in shares of Savara by 1,088.3% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock valued at $9,507,000 after buying an additional 1,687,310 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

About Savara

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Read More

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.